GMP Human BMP-4 / BMP2B Protein

  • Premium grade (Pre-GMP) version BM4-H5317 is now available for seamless transition.
Customer Reviews
Cat. No. / Size
Price
Qty
GMP-BM4H36-50ug
$758.00
GMP-BM4H36-1mg (50ug X 20)
$6838.00
GMP-BM4H36-10mg (50ug X 200)
$47866.00
ETA of in-stock products:2 business days

Product Details

  • Features

    1. Designed under ISO 9001:2015 and ISO 13485:2016
    2. Manufactured and QC tested under a GMP compliance factory
    3. Animal-Free materials
    4. Beta-lactam materials free
    5. Batch-to-batch consistency
    6. Stringent quality control tests
  • Source

    GMP Human BMP-4 Protein (GMP-BM4H36) is expressed from CHO cells. It contains AA Ser 293 - Arg 408 (Accession # P12644-1).

    Predicted N-terminus: Ser 293

    Request for sequence
  • Molecular Characterization

    BMP-4 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries no "tag".

    The protein has a calculated MW of 13.1 kDa. The protein migrates as 21 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 10 EU/mg by the LAL method / rFC method.

  • Host Cell Protein

    <0.5 ng/µg of protein tested by ELISA.

  • Host Cell DNA

    <0.02 ng/μg of protein tested by qPCR.

  • Sterility

    The sterility testing was performed by membrane filtration method described in USP<71> and Ph. Eur. 2.6.1.

  • Mycoplasma

    Negative

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 20 mM Citric acid, pH2.2 with protectants.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • Storage

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 5 years in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    BMP-4 SDS-PAGE

    GMP Human BMP-4 Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-CELL BASE

     BMP-4 CELL

    GMP Human BMP-4 Protein (Cat. No. GMP-BM4H36) stimulates Human BMP (Luc) HEK293 Reporter cells. The typical EC50 for this effect is 2.563 ng/mL (QC tested).

    Protocol
  • Application Data

     BMP-4 APPLICATION DATA

    GMP Human BMP-4 Protein (Cat. No. GMP-BM4H36) could promote the differentiation of iPSCs into hematopoietic stem and progenitor cells in a feeder-free system at Day 14, with high expression of CD34+ CD45+. GMP Human BMP-4 Protein (Cat. No. GMP-BM4H36) holds a similar performance with Human BMP-4 Protein, premium grade (Cat. No. BM4-H5317).

  • Bioactivity-Stability

     BMP-4 STABILITY

    The Cell based assay shows that GMP Human BMP-4 Protein (Cat. No. GMP-BM4H36) is stable at 37°C for 7 hours.

  •  BMP-4 STABILITY

    The Cell based assay shows that GMP Human BMP-4 Protein (Cat. No. GMP-BM4H36) is stable after freezing and thawing 3 times.

Customer Reviews
Writing Reviews

Background

Bone Morphogenetic Protein 4 (BMP4) is a member of growth factor of the TGF-beta superfamily that plays essential roles in many developmental processes, including neurogenesis, vascular development, angiogenesis and osteogenesis. BMP-4 Initiates the canonical BMP signaling cascade by associating with type I receptor BMPR1A and type II receptor BMPR2. BMP-4 can acts in concert with PTHLH/PTHRP to stimulate ductal outgrowth during embryonic mammary development and to inhibit hair follicle induction.

Important Statement

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.

    ACROBiosystems Quality Management System Contents:

    1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory
    2. Animal-Free materials
    3. Materials purchased from the approved suppliers by QA
    4. ISO 5 clean rooms and automatic filling equipment
    5. Qualified personnel
    6. Quality-related documents review and approve by QA
    7. Fully batch production and control records
    8. Equipment maintenance and calibration
    9. Validation of analytical procedures
    10. Stability studies conducted
    11. Comprehensive regulatory support files

    Request For Regulatory Support Files(RSF)

    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE
    2. Protein content
    3. Endotoxin level
    4. Residual Host Cell DNA content
    5. Residual Host Cell Protein content
    6. Biological activity analysis
    7. Microbial testing
    8. Mycoplasma testing
    9. In vitro virus assay
    10. Residual moisture
    11. Batch-to-batch consistency

  • DISCLAIMER

    ACROBiosystems GMP grade products are designed for research, manufacturing use or ex vivo use. CAUTION: Not intended for direct human use.

  • TERMS AND CONDITIONS

    All products are warranted to meet ACROBiosystems Inc.’s (“ACRO”) published specifications when used under normal laboratory conditions.

    ACRO DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, ACRO DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

    NOT WITH STANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN ACRO AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, ACRO’S TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO ACRO FOR THE RELEVANT PRODUCTS. IN NO EVENT WILL ACRO BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

  • END USER TERMS OF USE OF PRODUCT

    The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

    The End User is aware that ACROBiosystems Inc. and its affiliate (“ACRO”) sell GMP grade products designed for research, manufacturing use or ex vivo use and not intended for human in vivo applications. The End User further agrees, as a condition of the sales of ACRO’s GMP grade products that: a) the End User will not use this GMP grade product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the applicable review board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
  • Important Statement